|
Prior to cofounding Immunotope, Dr. Philip was Chief Scientific Officer of RHeoGene LLC beginning with its formation in July 1999. Prior to RHeoGene, he was Vice President for Gene Therapy Research at Argonex Inc., one of the two parent companies of RHeoGene. Prior to Argonex, Dr. Philip was the head of Vector Development and Oncology Department at Rhone Poulenc Rorer Gencell. Dr. Philip joined RPR Gencell in 1993 and had a key role in several gene therapy projects. He developed pMP6/Avectin vectors that were used in three approved clinical trials. In addition to overseeing vector development activities for p53, suicide/immunotherapy and antiangiogenesis projects, he also initiated the vector-targeting program at Gencell. From 1988 to 1993 he was a research scientist at Neurex Corporation, where he had a leadership role in cloning neuron specific calcium channels. Dr. Philip was also an Associate Professor of Research in Internal Medicine at the University of Virginia, Charlottesville. Dr. Philip received his Ph.D. from the Indian Institute of Science, Bangalore, India in Biological Sciences and did his postdoctoral work with Prof. D. Brutlag in Biochemistry Department at Stanford University. | 